Merus Labs Inc (Merus), a wholly owned subsidiary of Merus Labs International, has entered into a definitive agreement with Innocoll Pharmaceuticals Limited (Innocoll), under which Innocoll will market Merus's three wound care products for the Canadian market.
Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.
The three products are indicated for the management of painful wounds including diabetic ulcers, venous ulcers, pressure ulcers, full and partial thickness wounds, 1st and 2nd degree burns and dehisced surgical wounds.
Merus president and CEO Ahmad Doroudian said that they are very pleased to announce this strategic partnership with Innocoll to launch such unique products in Canada.
“This partnership with Innocoll will greatly enhance Merus’ pipeline of, ready to launch products in the Canadian market place, significantly enhancing patient care,” Doroudian said.